tbuckley/cabot-search huggingface dataset:
The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.
Authors: Kim De Keersmaecker, Pedro Jose Real Luna, Giusy Della Gatta, Teresa Palomero, Mireia Castillo, Maria Luisa Sulis, Valeria Tosello, Fotini Gounari, Barbara Kee, Jack Lenz, Michelle Kelliher, Peter D. Aplan, Carlos Cordon-Cardo, Adolfo A. Ferrando
Journal: Blood (2009)
Establishment of Novel Disease Models for Human Acute Type ATL and HTLV-I Carrier Using NOD-scid/IL2rgnull Mouse.
Authors: Chika Iwamoto, Fumihiko Ishikawa, Noriaki Kawano, Noriyuki Saito, Shen M. Yang, Mitsuhiro Fukata, Yoriko Saito, Leonard D. Shultz, Masao Matsuoka, Mine Harada
Journal: Blood (2007)
Long-term usability and bio-integration of polyimide-based intra-neural stimulating electrodes
Authors: S. Wurth, M. Capogrosso, S. Raspopovic, J. Gandar, G. Federici, N. Kinany, A. Cutrone, A. Piersigilli, N. Pavlova, R. Guiet, G. Taverni, J. Rigosa, P. Shkorbatova, X. Navarro, Q. Barraud, G. Courtine, S. Micera
Journal: Biomaterials (2017)
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Authors: Magnus Dillon, Sally Ellis, Lorna Grove, Lyndall McLellan, Glen Clack, Dr Simon Smith, Jennifer Laude, Zaid Viney, Sola Adeleke, George Lazaridis, James F. Spicer, Martin David Forster, Kevin J. Harrington
Journal: Journal of Clinical Oncology (2016)

TPS2603 Background: Tumour control rates from radiation therapy (RT) are limited by normal tissue toxicities. Novel strategies are required to selectively sensitize tumour cells to radiation-induced DNA damage. The G2 cell cycle checkpoint is an attractive target for this, as normal cells will be protected by their intact G1 checkpoint, which is lost in the majority of cancer cells. ATR is an important mediator of the G2 checkpoint. Preclinical data suggest that ATR inhibition will sensitise to DNA damaging therapies, including RT. This multi-part phase 1 trial aims to assess safety and tolerability and preliminary anti-tumour activity of the ATR inhibitor AZD6738 as monotherapy and in combination with palliative RT, escalating both drug and radiation dose at a dose-fractionation relevant to radical treatment. The design aims to test a novel agent at the earliest stage of clinical development and assess safety in combination with RT, with the aim of moving to a radically-treated population if tolerated. Methods: Participants have advanced solid tumours without standard systemic therapy options. The trial comprises three parts: parts A and B will assess AZD6738 as a single agent in dose escalation to MTD (part A), followed by expansion cohorts enriched for defective DNA damage response (part B). Part C will assess AZD6738 in combination with palliative RT in which participants will receive 20 Gy in 10 fractions, with per cohort escalation of drug dose to monotherapy MTD if tolerated. At the highest tolerated combination dose, the RT dose will be escalated to 30 Gy in 15 fractions. Maintenance AZD6738 post-RT will be tested at the highest tolerated combination dose. The study opened in August 2014. The study is dose escalating in part A and part C has opened and treated its first patient. Part B will open when dose escalation has completed. PATRIOT is sponsored by The Royal Marsden, funded by the Cancer Research UK/AstraZeneca Combinations Alliance and supported by supply of free drug and distribution costs from Astra Zeneca. Clinical trial information: NCT02223923.
Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results
Authors: Joshua D Brody, Debra Katherine Czerwinski, Victoria Carlton, Martin Moorhead, Jianbiao Zheng, Mark Klinger, Malek Faham, Ranjana Advani, Holbrook E Kohrt, Arash Ash Alizadeh, Robert S Negrin, Wen-Kai Weng, Kevin Sheehan, Ronald Levy
Journal: Blood (2011)
Targeting the Bcl-2 Family of Proteins in Hodgkin Lymphoma: In Vitro Cytotoxicity, Target Modulation and Drug Combination Studies of the BH3 Mimetic ABT-737
Authors: Aarthi Jayanthan, Scott C Howard, Tanya Trippett, Terzah M. Horton, Lara Daisley, Victor A. Lewis, Aru Narendran
Journal: Blood (2008)
Abstract 9443: Long-Term Clinical Outcomes of Infarct-Related Artery versus Multivessel Revascularization in Acute ST-Segment Elevation Myocardial Infarction with Multivessel Disease: An Analysis from Korea Acute Myocardial Infarction Registry
Authors: Han Cheol Lee, Jin Hee Choi, Bo Won Kim, Hye Won Lee, Mi Jin Yang, Sung Gyu An, Jun-Hyok Oh, Junghyun Choi, Kwang Soo Cha, Taek Jong Hong
Journal: Circulation (2011)

Many STEMI patients have multivessel disease. Guidelines recommend multiple revascularization only in cardiogenic shock. We compared clinical outcomes of multivessel revascularization with infarct-related artery(IRA) revascularization in ST-segment myocardial infarction(STEMI) patients. The 1,283 STEMI patients with multivessel disease[975 in IRA group(group I), 308 in multivessel group(group II)] received primary PCI and were analyzed from a nationwide Korea Acute Myocardial Infarction Registry. Primary outcomes were in-hospital mortality and 12-month major adverse cardiac events(MACE, defined as death, myocardial infarction, and repeated revascularization). Secondary outcomes were in-hospital complications and components of the MACE. There were more hemodynamic unstable patients in group I. In-hospital mortality was higher in group I with marginal significance(6.6% vs. 3.6%, p = 0.051). 12-month MACE occurred in 84(14.6%) in group I, 20(11.5%) in group II(p = 0.294). Each components of MACE were occurred similarly in two groups but non-target vessel revascularization(6.4% vs. 1.7%, p = 0.012). Adjusting for confounding factors, multivessel revascularization did not reduce in-hospital mortality(OR 0.935, 95% CI 0.403-2.167, p=0.875). It was same for 12-month MACE(OR 0.953, 95% CI 0.406-2.233, p = 0.911) and secondary outcomes. But multivessel revascularization reduced non-target vessel revascularization(OR 0.279, 95% CI 0.085-0.922, p = 0.036). There was no significant difference of clinical outcomes except for low risk of non-target vessel revascularization in multivessel revascularization group. Therefore, results of our study support current guidelines.
The Role of TWIST1 Gene Expression and Hypoxic Microenvironment in Acute Myeloid Leukemia
Authors: Emilia Carolina Malafaia, A. Mario Marcondes, Ekapun Karoopongse, Daniele Serehi, Maria de Lourdes L. F. Chauffaille, H. Joachim Deeg, Daniella M. Bahia Kerbauy
Journal: Blood (2015)
First Infant Formula Type and Risk of Islet Autoimmunity in The Environmental Determinants of Diabetes in the Young (TEDDY) Study
Authors: Sandra Hummel, Andreas Beyerlein, Roy Tamura, Ulla Uusitalo, Carin Andrén Aronsson, Jimin Yang, Anne Riikonen, Åke Lernmark, Marian J. Rewers, William A. Hagopian, Jin-Xiong She, Olli G. Simell, Jorma Toppari, Anette-G. Ziegler, Beena Akolkar, Jeffrey P. Krischer, Suvi M. Virtanen, Jill M. Norris
Journal: Diabetes Care (2017)

Studies on the introduction of infant formulas and its effect on the risk of islet autoimmunity and type 1 diabetes (T1D) have yielded inconsistent results. We investigated whether the introduction of formula based on hydrolyzed cow's milk as the first formula is associated with reduced islet autoimmunity risk in a large prospective cohort.
Diabetes Outpatient Care and Acute Complications Before and After High-Deductible Insurance Enrollment
Authors: J. Frank Wharam, Fang Zhang, Emma M. Eggleston, Christine Y. Lu, Stephen Soumerai, Dennis Ross-Degnan
Journal: JAMA Internal Medicine (2017)

High-deductible health plans (HDHPs) have expanded under the Affordable Care Act and are expected to play a major role in the future of US health policy. The effects of modern HDHPs on chronically ill patients and adverse outcomes are unknown.To determine the association of HDHP with high-priority diabetes outpatient care and preventable acute complications.Controlled interrupted-time-series study using a large national health insurer database from January 1, 2003, to December 31, 2012. A total of 12 084 HDHP members with diabetes, aged 12 to 64 years, who were enrolled for 1 year in a low-deductible (≤$500) plan followed by 2 years in an HDHP (≥$1000) after an employer-mandated switch were included. Patients transitioning to HDHPs were propensity-score matched with contemporaneous patients whose employers offered only low-deductible coverage. Low-income (n = 4121) and health savings account (HSA)-eligible (n = 1899) patients with diabetes were subgroups of interest. Data analysis was performed from February 23, 2015, to September 11, 2016.Employer-mandated HDHP transition.High-priority outpatient visits, disease monitoring tests, and outpatient and emergency department visits for preventable acute diabetes complications.In the 12 084 HDHP members included after the propensity score match, the mean (SD) age was 50.4 (10.0) years; 5410 of the group (44.8%) were women. The overall, low-income, and HSA-eligible diabetes HDHP groups experienced increases in out-of-pocket medical expenditures of 49.4% (95% CI, 40.3% to 58.4%), 51.7% (95% CI, 38.6% to 64.7%), and 67.8% (95% CI, 47.9% to 87.8%), respectively, compared with controls in the year after transitioning to HDHPs. High-priority primary care visits and disease monitoring tests did not change significantly in the overall HDHP cohort; however, high-priority specialist visits declined by 5.5% (95% CI, -9.6% to -1.5%) in follow-up year 1 and 7.1% (95% CI, -11.5% to -2.7%) in follow-up year 2 vs baseline. Outpatient acute diabetes complication visits were delayed in the overall and low-income HDHP cohorts at follow-up (adjusted hazard ratios, 0.94 [95% CI, 0.88 to 0.99] for the overall cohort and 0.89 [95% CI, 0.81 to 0.98] for the low-income cohort). Annual emergency department acute complication visits among HDHP members increased by 8.0% (95% CI, 4.6% to 11.4%) in the overall group, 21.7% (95% CI, 14.5% to 28.9%) in the low-income group, and 15.5% (95% CI, 10.5% to 20.6%) in the HSA-eligible group.Patients with diabetes experienced minimal changes in outpatient visits and disease monitoring after an HDHP switch, but low-income and HSA-eligible HDHP members experienced major increases in emergency department visits for preventable acute diabetes complications.
Absence of JAK2 V617F Activating Mutations in Children with Acute Megakaryoblastic Leukemia with and without Down Syndrome.
Authors: Christian M. Zwaan, Mathilde J.C. Broekhuis, Claudia Langebrake, Bianca F. Goemans, Gertjan J.L. Kaspers, Rob Pieters, Dirk Reinhardt, Monique L. den Boer
Journal: Blood (2006)
Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure
Authors: Ravi Vij, Craig C. Hofmeister, Paul G. Richardson, Sundar Jagannath, David S. Siegel, Rachid Baz, Min Chen, Mohamed Zaki, Gail Larkins, Kenneth C. Anderson
Journal: Blood (2012)
A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms
Authors: David A. Hinds, Kimberly E. Barnholt, James L. Zehnder, Amy K. Kiefer, Chuong B. Do, Nicholas Eriksson, Joanna L. Mountain, Uta Francke, Joyce A. Tung, Huong (Marie) Nguyen, Ross L. Levine, Ruben A. Mesa, Jason Gotlib
Journal: Blood (2012)
Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.
Authors: Martina Kleber, Peter Haas, Bernd Koch, Manuela Burbeck, Monika Engelhardt
Journal: Blood (2009)
Abstract P354: Reported Prevalence of High Blood Pressure and Cholesterol among US Adults - Behavioral Risk Factor Surveillance System, 2011
Authors: Fleetwood Loustalot, Jing Fang
Journal: Circulation (2013)

Background: High blood pressure and cholesterol are leading risk factors for cardiovascular disease (CVD). The Behavioral Risk Factor Surveillance System (BRFSS) is currently the only system that can provide state-level estimates of high blood pressure and cholesterol, and states frequently use the BRFSS when monitoring CVD risk factors. Several methodological changes to the BRFSS were instituted in 2011, to account for rising rates of cellular phone only households and declining response rates. The improvements may result in shifts to state-level estimates, and comparisons with previous years may represent methodological changes, rather than risk factor improvement or worsening. New baseline data are needed and this study uses the most recent data to report high blood pressure and cholesterol estimates among US states. Methods: The BRFSS is a state-based, random-digit-dialed telephone survey of non-institutionalized US adults aged ≥18 years. High blood pressure and cholesterol are assessed in odd years, using: “Have you ever been told by a doctor, nurse, or other health professional that you have high blood pressure [¼your high blood cholesterol is high]?” Data were analyzed by age, sex, race/ethnicity, education, and state. All estimates were age standardized using the 2000 US standard projected population. Analyses were conducted using SAS-callable SUDAAN to account for the complex sampling design. Within group differences were assessed using pairwise comparisons. The analytic sample was 498,201. Results: Overall, 30.3% (95% Confidence Interval: 30.0-30.5%) reported high blood pressure and 34.0% (33.7-34.3%) high cholesterol. Compared with other demographic groups, higher estimates of high blood pressure were reported among males, those with &lt; a high school education, non-Hispanic blacks, and those ≥65 years. In parallel, high cholesterol was most commonly reported among males, those with &lt; a high school education, and those ≥65 years, with non-Hispanic blacks reporting the lowest prevalence, compared with other demographic groups. By state, reported high blood pressure ranged from 24.7% (Colorado) to 38.3% (Mississippi) and high cholesterol from 28.0% (Montana) to 37.8% (Texas). Conclusions: In 2011, about 1 in 3 US adults reported high blood pressure and high cholesterol. Marked demographic and geographic disparities were found. Coordinated community and clinical interventions are needed to address the high burden of high blood pressure and cholesterol. For example, the Million Hearts TM initiative, a public-private partnership, seeks to align, coordinate, and enhance activities across the US, with prevention and treatment of high blood pressure and cholesterol being key components of the initiative.
Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).
Authors: Stefan Faderl, Deborah A. Thomas, Varsha Gandhi, Gautam Borthakur, Xuelin Huang, William Plunkett, Jan Burger, Jorge Cortes, Susan O’Brien, Farhad Ravandi, Jennie Bretz, Monica Kwari, Hagop M. Kantarjian
Journal: Blood (2007)
Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide ± Dexamathosone in AL Amyloidosis.
Authors: Angela Dispenzieri, Martha Lacy, Steven Zeldenrust, Suzanne R. Hayman, Shaji Kumar, Susan M. Geyer, John A. Lust, Jacob B. Allred, Thomas E. Witzig, S. Vincent Rajkumar, Philip R. Greipp, Stephen J. Russell, Brian Kabat, Morie Abraham Gertz
Journal: Blood (2006)
Mixed Phenotype Acute Leukemia (MPAL) Has a High Frequency of Mutations in Epigenetic Regulatory Genes: Results from Whole Exome Sequencing
Authors: Olive S. Eckstein, Linghua Wang, Jyotinder N. Punia, Steven M. Kornblau, Michael Andreef, David A. Wheeler, Margaret A. Goodell
Journal: Blood (2014)
Extramedullary Acute Leukemias prior to and after Allogeneic Hematopoietic Stem Cell Transplantation: a Single Center Study.
Authors: Michael Stadler, Helmut Diedrich, Elke Dammann, Stefanie Buchholz, Eva Mischak-Weissinger, Juergen Krauter, Matthias Eder, Arnold Ganser
Journal: Blood (2008)
Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools
Authors: Kasper Lamberth, Stine Louise Reedtz-Runge, Jonathan Simon, Ksenia Klementyeva, Gouri Shankar Pandey, Søren Berg Padkjær, Véronique Pascal, Ileana R. León, Charlotte Nini Gudme, Søren Buus, Zuben E. Sauna
Journal: Science Translational Medicine (2017)

A computational and experimental strategy assesses the immunogenicity risk of bioengineered therapeutic proteins.
Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse
Authors: Naga Poojitha Ojamies, Mika Kontro, Maija Wolf, Henrik Edgren, Pekka Ellonen, Sonja Lagström, Tiina Hannunen, Tea Pemovska, Henrikki Almusa, Maija Lepistö, Caroline A Heckman, Krister Wennerberg, Kimmo Porkka, Olli Kallioniemi
Journal: Blood (2014)
Familial outbreak of eruptive pseudoangiomatosis with dermoscopic and histopathologic correlation
Authors: Carlos Gustavo Wambier, Mark Aaron Cappel, Tayza Katelline Danilau Ostroski, Mário Rodrigues Montemor Netto, Sarah Perillo de Farias Wambier, Bruna Lais Santos de Jesus, Eurico Arruda
Journal: Journal of the American Academy of Dermatology (2017)
Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature.
Authors: Charles Blake Hutchinson, Jennifer H. Crow, Qin Huang, Chuanyi M. Lu, Siby Sebastain, Catherine Rehder, Anand S. Lagoo, Barbara Goodman, Mitchell E. Horwitz, David A. Rizzieri, Michael Datto, Patrick Buckley, Endi Wang
Journal: Blood (2010)
T Cell-Mediated Control of HCMV Infection in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
Authors: Franco Locatelli, Daniele Lilleri, Laura Lozza, Giovanna Giorgiani, Piero De Stefano, Chiara Fornara, Stefania Telli, Rita Maccario, Maria Grazia Revello, Giuseppe Gerna
Journal: Blood (2004)
Investigating avoidable patient deaths
Authors: Margaret Murphy
Journal: BMJ (2017)

Families must come first, not corporate damage limitation

The Care Quality Commission’s (CQC) review of the way in which NHS trusts review and investigate the deaths of patients in England makes for sobering reading.1 It emphasises that learning from deaths needs to be given much greater priority within the NHS to avoid missing opportunities to improve care.1

The review also found that no trust had good practice across all aspects of identifying, reviewing, and investigating deaths and ensuring that learning is implemented, but that some trusts showed promising practice at individual steps.1 This comes as a welcome affirmation for patients and families, and as a validation of how they have, all too often, described their unsatisfactory experiences of interactions with healthcare services and professionals in the aftermath of adverse events.2 The experiences of the World Health Organization’s Patients for Patient Safety cohort, representative of over 50 countries, are testament to the …
Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs
Authors: Jacob Meacham Smith, Josiah D. Rich
Journal: Hepatology (2017)

Dr Rich and this work were partly supported by grants K24DA022112 and P30AI042853. Potential conflict of interest: Dr. Rich owns stock in Alkermes. To the Editor: Cousiens et al. present an important model of changes in the hepatitis C epidemic among persons who inject drugs based upon scenarios of improved diagnosis, linkage to care, and access to treatment in the era of effective direct‐acting antiviral agents.1 Their model predicts reductions in transmission of hepatitis C at 10 years with access to treatment earlier in the course of chronic hepatitis C infection. Many individuals who inject drugs have the disease of opioid use disorder. This is a disease for which we have highly effective therapy with methadone, buprenorphine, or injectable naltrexone. We are concerned that their model does not include treatment for opioid use disorder, which is known to reduce hepatitis C transmission.2 This issue is even more relevant for the United States, where we are experiencing an epidemic of opioid use disorder and have far less availability of buprenorphine than in France. In France any doctor can prescribe buprenorphine.3 In the United States physicians must obtain a specific waiver to prescribe buprenorphine; in 2011 there were on average just seven prescribers per county.4 Infectious disease physicians, hepatologists, and other physicians providing care for persons who inject drugs should also lower the risk of hepatitis C infection or reinfection after effective treatment by addressing the underlying opioid use disorder, either through directly prescribing medication‐assisted therapy or directly linking to another physician who prescribes medication‐assisted therapy. Cousiens et al. note that treatment of hepatitis C infection is not the only way to reduce transmission. In modeling the care cascade for hepatitis C infection among persons who inject drugs, attention must be paid to better prevention of hepatitis C transmission along with diagnosis, linkage to care, and access to treatment. This includes increased access to medication‐assisted treatment of opioid use disorder. In both mathematical modeling and clinical care it is critical to champion the use of the most effective evidence‐based treatments for the underlying disorder.
Team meetings do not devote enough time to complex cancer cases, report warns
Authors: Anne Gulland
Journal: BMJ (2017)

Doctors and other staff members spend an average of just 3.2 minutes discussing each patient during multidisciplinary team meetings, a report by Cancer Research UK has found.1

The report called for an overhaul of the running of multidisciplinary team meetings where cancer patients’ diagnosis, treatment, and care are discussed. It said that they are a drain on staff resources and do not devote enough time to complex cases.

The report says that since the meetings were introduced in 1995 the NHS has changed dramatically, with a huge increase in demand and only minor increases in capacity. In 2014-15 around 1.4 …